Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

The Danish crown weakened on Friday, after disappointing results from a late-stage trial of a new weight-loss drug drove a ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong ...

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management.

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk ...

Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...